Inactivated influenza vaccines: Pre-vaccination haemagglutinin-antibody titres influence the vaccine response but not necessarily the vaccine effectiveness

Drugs and Aging

Volumn 28, Issue 6, 2011, Pages 505-

  Lang, Pierre Olivier ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ;

ANTIBODY TITER; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; LETTER; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS INHIBITION;

ADJUVANTS, IMMUNOLOGIC; AGING; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 79958276801     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11592350-000000000-00000     Document Type: Letter

References (5)

1. Parodi V, de Florentiis D, Martini M, et al. Inactivated influenza vaccines: recent progress and implications for the elderly. Drugs Aging 2011; 28 (2): 93-106
2. Lang PO, Govind S, Mitchell WA, et al. Vaccine effectiveness in older individuals: what has been learned from influenzavaccine experience. Ageing Res Rev 2011; 10 (3): 389-95
3. Feng JQ, Gulati U, Zhang X, et al. Antibody quantity versus quality after influenza vaccination. Vaccine 2009; 27: 6358-62
4. Lang PO, Govind S, Mitchell WA, et al. Influenza vaccine effectiveness in aged individuals: the role played by cellmediated immunity. Eur Ger Med 2010; 1: 233-8
5. Gijzen K, Liu WM, Visontai I, et al. Standardization and validation of assays determining cellular immune responses against influenza. Vaccine 2010; 28: 3416-22